Principal Investigator (PI) handovers in clinical trials are high-risk moments for Good Clinical Practice (GCP) compliance. One of the most common documentation failures during a PI transition is a gap in the clinical trial delegation log, which records who is authorised to perform study-related duties on behalf of the investigator.
When this documentation breaks down, sites must determine whether the issue represents an administrative delay or a major GCP non-compliance.
Principal Investigator Handover & Delegation Log Gaps in Clinical Trials
Let’s set the scene with this real-life scenario.
“The previous Principal Investigator discontinued staff delegations on 12 January 2026. However, due to significant operational and staffing challenges at the site, and the absence of a structured handover process, no new delegation log was initiated by the incoming PI at that time. Despite this, site staff continued to conduct study visits and patient care activities, as participants required ongoing medical oversight…”
The key question becomes:
How Should a Clinical Trial Site Address a Delegation Log Gap from 12 January 2026 to the Present?
Two possible approaches may typically be considered.
Option 1
The new PI opens a delegation log and delegates staff effective from the date of formal oversight (i.e., now), leaving a documented gap that requires a Note to File.
Option 2
The new PI opens a delegation log reflecting continuity from 12 January 2026, with appropriate documentation (i.e., start date of 12 January 2026 but signed and dated today) and a Note to File explaining the delayed administrative correction.
The question is:
Can either option be chosen as long as it is documented?
The answer is:
It depends.
And to make a responsible decision, you need more background information.
Questions That Must Be Asked Before Correcting a Clinical Trial Delegation Log
Before touching the delegation log, pause.
Regulatory decisions in clinical research should never be reactive.
PI 1 (Outgoing Principal Investigator)
• The PI stopped all staff on the delegation log on 12 January 2026
• Were authorities notified of these stop dates? This is a crucial question, as it would imply that none of the staff were approved to work on the trial after this date.
• If no notification was sent — which is likely, because staff continued performing study duties — then technically they were still operating under previously approved roles while caring for participants.
• Were authorities notified of the PI change?
PI 2 (Incoming Principal Investigator)
• Has the new PI been approved by the sponsor and regulatory authorities? If so, what is the approval date?
• Has the PI undergone documented protocol training before assuming their duties?
• Did the PI sign the protocol signature page and Investigator Brochure (IB) demonstrating knowledge of the study?
• Was the Clinical Trial Agreement (CTA) amended, or was the FDA Form 1572 updated?
• When did contractual responsibility formally transfer?
• Were Informed Consent Forms (ICFs) updated with the new PI information?
• Were participants re-consented?
The Period: 12 January 2026 – Present
• Was there a protocol amendment during this period?
• Did any new staff join the trial?
• Did the incoming PI review or sign off on staff training?
• Is there evidence in source documentation of PI oversight during this period?
• Were AEs or SAEs reviewed and assessed by the new PI?
• Is there proof the PI was physically present or remotely supervising the study?
These answers determine whether you are correcting an administrative delay or attempting to retrospectively assign responsibility where none existed.
The Clinical Trial Delegation Log: Governance vs Reality
Here is the core principle:
A clinical trial delegation log should reflect actual investigator oversight and responsibility, not merely administrative timing.
If the new PI was:
• Approved by sponsor and authorities by 12 January 2026
• Trained on the protocol and Investigator Brochure
• Contractually engaged
• Actively providing oversight (as evidenced in source documentation)
Then the situation is likely an administrative documentation failure, not an absence of oversight.
In that case, the defensible approach would be:
Open a new delegation log with:
• PI start date: 12 January 2026
• Signature date: today
• Staff listed with start date of 12 January 2026
• Authorisation signature applied today
• Clear explanatory documentation attached
Depending on site policy, some sites prefer not to open a new log during a PI handover. Instead, the new PI may stop the previous PI on the delegation log, review each entry, and counter-sign each line to confirm authorisation to continue delegated duties.
However, in this scenario the delegation log was already closed by the previous PI by adding stop dates to all staff. Therefore, a new delegation log must be opened.
Why Delegation Logs Matter in Clinical Trial Compliance
In clinical trials, the delegation log is a core essential record required under Good Clinical Practice (GCP). It demonstrates that the Principal Investigator has appropriately delegated study responsibilities to qualified staff and maintains oversight of study activities.
During a Principal Investigator handover, failure to properly update the delegation log can create uncertainty about who was authorised to perform study procedures and a gap in who ultimately took responsibility for participant safety and data integrity. This may raise concerns during monitoring visits, audits, or regulatory inspections.
Required Documentation When Correcting a Delegation Log Gap
This correction must be accompanied by a comprehensive Note to File documenting:
• Last active date of the outgoing PI
• Date of sponsor and regulatory authority approval of the new PI
• Date of protocol and IB signature pages
• Date of CTA amendment or FDA 1572 update
• Confirmation that ICFs were updated, or explanation if delayed
• Confirmation that no protocol amendment occurred during the gap period
• Confirmation that staff remained qualified and previously delegated
• Confirmation that participants required continuous clinical oversight
Critically, attach evidence of day-to-day PI oversight during this period.
If oversight was real — document it. If it was not — do not fabricate continuity.
When a Delegation Log Gap Becomes a Major GCP Non-Compliance
If the incoming PI was not:
• Approved
• Trained
• Contractually engaged
• Reviewing safety data
• Providing actual oversight
Then responsibility cannot be retrospectively assigned.
In this situation the correct approach is:
• Open the delegation log effective from the true date of oversight
• Transparently document the gap
• Escalate the issue to the sponsor and regulatory authorities
• Log the issue as a major GCP non-compliance
Attempting to create retroactive delegation without evidence creates far greater regulatory risk.
Preventing Delegation Log Gaps During Principal Investigator Handover
In almost every case like this, the root cause is the same:
There was no structured PI handover process.
The outgoing PI stopped delegations.
The incoming PI stepped in clinically.
But no one owned the regulatory transition.
And that is how governance gaps are born.
Every research site should implement a formal PI Handover Checklist covering:
• Sponsor approval
• Ethics submissions
• CTA / FDA 1572 updates
• Delegation log closure and opening
• Oversight discussion documentation
• Safety review handover
• Participant communication
• Final signed transfer acknowledgement
Because Principal Investigator handover is not administrative. It is a transfer of legal and regulatory responsibility.
Final Thought
When faced with a delegation log gap, the question is not:
“How do we fix the log?”
The question is:
“What actually happened in practice — and how do we transparently document that reality?”
Good Clinical Practice is not about perfection.
It is about honesty, traceability, and documented oversight.
If you want to ensure this never happens at your site:
